A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY110140 in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 23 May 2016
At a glance
- Drugs Fluoxetine (Primary)
- Indications Depressive disorders; Obsessive-compulsive disorders; Panic disorder; Premenstrual dysphoric disorder
- Focus Adverse reactions
- Sponsors Eli Lilly
- 19 Sep 2012 Planned End Date changed from 1 Oct 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.